PuSH - Publication Server of Helmholtz Zentrum München

Schreyögg, J. ; Weller, J. ; Stargardt, T.* ; Herrmann, K.* ; Bluemel, C.* ; Dechow, T.* ; Glatting, G.* ; Krause, B.J.* ; Mottaghy, F.* ; Reske, S.N.* ; Buck, A.K.*

Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.

J. Nucl. Med. 51, 1668-1675 (2010)
Publ. Version/Full Text Volltext DOI PMC
Free by publisher
Open Access Green as soon as Postprint is submitted to ZB.
Although the diagnostic effectiveness of integrated PET/CT for staging of non-small cell lung cancer (NSCLC) has already been proven, it remains to be determined if tumor staging with combined metabolic and anatomic imaging is also cost-effective. The objective of this study was to evaluate from a payers' perspective the cost-effectiveness of staging NSCLC with CT alone (representing the mainstay diagnostic test) and with integrated PET/CT. The study is based on 172 NSCLC patients from a prospective clinical study who underwent diagnostic, contrast-enhanced helical CT and integrated PET/CT. Imaging was performed at the University Hospital Ulm between May 2002 and December 2004. To calculate treatment costs, we differentiated among cost for diagnosis, cost for nonsurgical treatment according to the clinical diagnosis, and cost for surgical procedures according to the clinical tumor stage. The diagnostic effectiveness in terms of correct TNM staging was 40% (31/77) for CT alone and 60% (46/77) for PET/CT. For the assessment of resectability (tumor stages Ia-IIIa vs. IIIb-IV), 65 of 77 patients (84%) were staged correctly by PET/CT (CT alone, 70% [54/77]). The incremental cost-effectiveness ratios per correctly staged patient were $3,508 for PET/CT versus CT alone. The incremental cost-effectiveness ratios per quality-adjusted life year gained were $79,878 for PET/CT vs. CT alone, decreasing to $69,563 assuming a reduced loss of utility (0.10 quality-adjusted life years) due to surgical morbidity.Cost-effectiveness analyses showed that costs for PET/CT are within the commonly accepted range for diagnostic tests or therapies. Therefore, reimbursement of PET/CT for NSCLC staging can be also recommended from an economic point of view.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords cost-effectiveness analysis; quality-adjusted life year; hybrid PET/CT; non-small cell lung cancer; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; COMPUTED-TOMOGRAPHY; CLINICAL-TRIALS; CT
ISSN (print) / ISBN 0161-5505
e-ISSN 1535-5667
Journal Journal of Nuclear Medicine
Quellenangaben Volume: 51, Issue: 11, Pages: 1668-1675 Article Number: , Supplement: ,
Publisher Society of Nuclear Medicine and Molecular Imaging
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Health Economics and Health Care Management (IGM)